Corpus Intelligence IC Memo — OCHSNER CLINIC FOUNDATION 2026-04-26 05:20 UTC
IC Memo — OCHSNER CLINIC FOUNDATION
Investment Committee Memorandum | LA | 1024 beds | Grade C | EBITDA uplift $148.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

OCHSNER CLINIC FOUNDATION

CCN 190036 | nan, LA | 1024 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

OCHSNER CLINIC FOUNDATION is a 1024-bed large academic medical center in nan, LA with $2.02B in net patient revenue and a -13.8% operating margin. The hospital serves a payer mix of 14.6% Medicare, 0.9% Medicaid, and 84.4% commercial.

Thesis: Undervalued. Our ML models identify $148.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -13.8% to -6.4% (+736bps).

Net Revenue HCRIS$2.02B
Current EBITDA COMPUTED$-278.1M
Operating Margin COMPUTED-13.8%
Occupancy HCRIS64.7%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS29.8%
Distress Probability ML45.3%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
261
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -13.8% places it below the state median. Among 261 size-comparable peers (512-2048 beds), the median margin is -4.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (512-2048), prioritizing same-state peers. 261 hospitals in the comp set.

HospitalStateBedsRevenueMargin
OCHSNER CLINIC FOUNDATION (Target)LA1024$2.02B-13.8%
ST. LUKES HOSPITALPA633$8.94B87.9%
NYU LANGONE HOSPITALSNY1618$7.24B-7.8%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $148.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$42.4M+210bp18mo
Cost to Collect4.5%2.5%$40.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$40.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$24.6M+122bp9mo
Clean Claim Rate88.0%96.0%$1.3M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$42.4M
Cost to Collect
$40.4M
Denial Rate Reduction
$40.0M
A/R Days Reduction
$24.6M
Clean Claim Rate
$1.3M
Total EBITDA Uplift$148.7M
Current EBITDA$-278.1M
+ RCM Uplift+$148.7M
Pro Forma EBITDA$-129.4M
Current Margin-13.8%
Pro Forma Margin-6.4%
WC Released (1x)$77.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-427.8M$-347.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-427.8M$-521.3M0.00x-100.0%
Bull Case9.0x11.0x$-385.0M$-169.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-385.0M$-298.7M0.00x-100.0%
Bear Case11.0x10.0x$-470.6M$-952.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-470.6M$-1.20B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 261 hospitals with 512-2048 beds
  • Same-state prioritization (n=3)
  • Comp margins: P25=-15.7% / P50=-4.6% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.